An Open Label, Randomized 3-Way Crossover Single Dose Study To Compare The Pharmacokinetics And Relative Bioavailability Of PF-04191834 Using An Oral Wet-Milled Suspension Formulation Versus An Oral Single Dose Dispersion Formulation Under Fasted Conditions In Healthy Volunteers
Latest Information Update: 21 Oct 2015
At a glance
- Drugs PF 4191834 (Primary)
- Indications Asthma; Osteoarthritis; Pain
- Focus Pharmacokinetics
- Sponsors Pfizer
- 18 Jan 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 27 Dec 2010 New trial record